Facebook is the social media platform most pharma marketers plan to use in the next two years, followed by YouTube, LinkedIn and Twitter.

How do you get 100% of the payers you approach to cover a pricey new med? Mitsubishi Tanabe’s commercial chief has an idea.

Novartis' Entresto to treat heart failure had a tough launch at $4,600 a year, but the product is starting to turn around.

Fanapt maker Vanda has launched a national TV awareness campaign about akathisia, a little-known side effect of some schizophrenia drugs.

Not every baseball fan wants peanuts and Cracker Jack—especially fans with severe allergies. But Kaléo has a solution.

Tesaro’s PARP contender Zejula has only been around since April, but that’s all the time it needed to snag the No. 1 position in the space.

It wasn’t long ago that Lundbeck was struggling. But thanks to some new launches, the company is poised to post its best-ever financial year.

Amgen debuted a Prolia TV ad with longtime spokesperson Blythe Danner, just weeks after a setback for its next-gen osteoporosis med romosozumab.

Marketing